From basic and clinical studies on KW-1062, the following results were obtained.
1) Antibacterial activity of KW-1062 against various clinically isolated organisms, such as Staphylococcus aureus, E. coli, Klebsiella, Proteus sp. and Pseudomonas aeruginosa was tested.
The M. I. C. s of KW-1062 were almost distributed at less than 12. 5 μg/ml and those of 70% of organisms were less than 1. 56 μg/ml.
Antibacterial activity of KW-1062 was found to be similar to that of gentamicin or less than that of gentamicin.
2) KW-1062 were administered at a daily dose of 80 to 240 mg (6-35 days) to 7 patients comprising 6 cases of respiratory tract infections and one case of sepsis.
Excellent response was observed in one with sepsis and good effect was obtained in 4 oat of 6 patients with respiratory tract infections.
Transient hearing impairment and slight elevation of BUN were observed in one patient who was given a daily dose of 240 mg. No other side effects were encountered.
